Arya Roy

Jan 17, 2025 | oncologynewscentral.com | Arya Roy |Sarah L. Sammons

At the Oncology Brothers live event, Advancements in Oncology, coinciding with SABCS in San Antonio, Dr. Arya Mariam Roy (The Ohio State University Comprehensive Cancer Center) interviewed Dr. Sarah Sammons (Dana-Farber Cancer Institute, Harvard Medical School), who served on the Triple-Negative Breast Cancer panel.

Jan 17, 2025 | oncologynewscentral.com | Arya Roy |Neil M. Iyengar

This interview, recorded during the Oncology Brothers live event, Advancements in Oncology, which coincided with SABCS in San Antonio, features Dr. Arya Mariam Roy (The Ohio State University Comprehensive Cancer Center) interviewing Dr. Neil Iyengar (Memorial Sloan Kettering Cancer Center).

Jan 17, 2025 | oncologynewscentral.com | Arya Roy |Margaret E. Gatti-Mays

At the Oncology Brothers live event, Advancements in Oncology, during SABCS in San Antonio, Dr. Arya Mariam Roy (The Ohio State University Comprehensive Cancer Center) interviewed Dr. Margaret Gatti-Mays, also from The Ohio State University Comprehensive Cancer Center, who served on the Triple-Negative Breast Cancer panel where the importance of the OlympiA trial update was highlighted, emphasizing its compelling survival data and its critical role in guiding treatment decisions for community...

Jul 15, 2024 | onclive.com | Arya Roy

Arya Mariam Roy, MBBS, fellow, Hematology/Oncology, Roswell Park Comprehensive Cancer Center, discusses limitations of the Pathway trial evaluating the association between polygenic scores (PGS) and survival outcomes in patients with breast cancer, and explains ways investigators plan to address these limitations. Pathway was a prospective cohort study that gathered genome-wide genotype data from 3995 patients with breast cancer who were enrolled from 2006 to 2013.

Jun 14, 2024 | onclive.com | Arya Roy

CommentaryVideoJune 14, 2024Author(s):Arya Mariam Roy, MBBS, discusses the role of polygenic scores in predicting the risk of recurrence and survival outcomes in breast cancer. Arya Mariam Roy, MBBS, fellow, Hematology/Oncology, Roswell Park Comprehensive Cancer Center, discusses findings from the Pathway trial—a prospective cohort study—evaluating the association between polygenic scores (PGS) and survival outcomes in patients with breast cancer.